Expert hematologist-oncologist Rafael Fonseca, MD, reviews the diagnosis and management of an 81-year-old-man who presents with transplant-ineligible multiple myeloma.
EP. 1: A Case of Transplant-Ineligible MM: Frontline Daratumumab-based Triplet Therapy
Rafael Fonseca, MD, provides details on a patient case of transplant-ineligible multiple myeloma and reviews the selection of frontline triplet versus doublet therapy.
EP. 2: Updated Data from the MAIA Trial in Transplant-Ineligible MM
Expert perspectives on updated data from the MAIA trial in newly diagnosed transplant-ineligible multiple myeloma and how this can be applied to clinical practice.
EP. 3: Optimizing the Management of Transplant-Ineligible NDMM: Depth and Durability of Response
Practical advice on strategies to improve care for patients with transplant-ineligible multiple myeloma regarding induction and maintenance therapy, and aiming for deep and durable responses.
EP. 4: Treatment Armamentarium for Relapsed/Refractory Multiple Myeloma
Rafael Fonseca, MD, shares an overview of the treatment armamentarium for patients with relapsed/refractory multiple myeloma.
EP. 5: Novel CAR T-Cell Therapies for Relapsed/Refractory Multiple Myeloma
Shared insight on two novel CAR T-cell therapies, cilta-cel and ide-cel, that have been tested in multiply relapsed multiple myeloma.
EP. 6: Novel Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma
Expert perspectives on two bispecific antibodies, teclistamab and talquetamab, that have been investigated in multiply relapsed multiple myeloma.
EP. 7: Evolving Treatment Options for Transplant-Ineligible Multiple Myeloma
Before closing out his discussion on transplant-ineligible multiple myeloma, Rafael Fonseca, MD, considers the future roles of CAR T-cell and bispecific antibody therapies.
2 Clarke Drive Cranbury, NJ 08512